Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tumor-Associated Antigen-Specific T Cells
- Development stage
- Phase 1
- Lead developer
- Children's National Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Tumor-Associated Antigen-Specific T Cells (TAA-T) is an adoptive cell therapy consisting of T cells that have been expanded and activated to recognize multiple tumor-associated antigens (TAAs), such as Wilms Tumor 1 (WT1), PRAME, and Survivin. Unlike CAR-T cell therapies, TAA-Ts are typically non-genetically modified and rely on their native T-cell receptors (TCRs) to recognize antigens presented by human leukocyte antigen (HLA) molecules on the surface of tumor cells. This approach allows for the targeting of multiple antigens simultaneously, which may help prevent immune escape due to antigen loss. TAA-T products can be manufactured from the patient's own cells (autologous) or from healthy donors (allogeneic/off-the-shelf). Clinical development has focused on hematologic malignancies like Hodgkin lymphoma and various pediatric solid tumors, including osteosarcoma and neuroblastoma.
- Other names
- Tumor-Associated Antigen-Specific T CellsMulti-Tumor-Associated Antigen-Specific T Cells
02
Targets
PRAME peptide–HLA complexHLA-A*02 (Human leukocyte antigen A*02 complexed peptide)Sur1M2-HLA-A2 (Survivin-derived peptide–Major Histocompatibility Complex)
Beyond the preview
Go deeper on Tumor-Associated Antigen-Specific T Cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-Associated Antigen-Specific T Cells.